The largest database of trusted experimental protocols
> Anatomy > Body Space or Junction > Knee Joint

Knee Joint

The knee joint is a complex hinge joint that connects the thigh and lower leg, allowing for flexion, extension, and limited rotation.
It is composed of the femur, tibia, and patella bones, as well as ligaments, tendons, and cartilage that facilitate smooth movement and weight-bearing.
Proper knee joint function is essential for ambulation and many physical activities.
Disorders affecting the knee joint, such as osteoarthritis, ligament tears, and patellofemoral pain, can lead to pain, stiffness, and impaired mobility.
Accurate assessement and treatment of knee joint conditions is an important area of medical research and clinical practice.
Expereience the power of AI-driven protocol analysis today to optimize your knee joint studies.

Most cited protocols related to «Knee Joint»

All images were acquired using a whole-body Philips 3T Achieva scanner (Philips Medical System, Best, The Netherlands) equipped with 80 mT/m gradients. RF was transmitted using the body coil and SENSE reception (31 (link)) was employed. A series of consecutive direct saturation and CEST scans were performed using the 8-element knee coil for both the glycogen phantom and in vivo human calf muscle. To minimize leg motion, foam padding was placed between the subject’s lower leg and the knee coil. In all cases, second order shims over the entire muscle on the imaging slice were optimized to minimize B0 field inhomogeneity. Notice that the width of Z-spectra depends on T2 and that the WASSR procedure provides an absolute field frequency map so that there is no need for higher order shimming for the CEST acquisition. Clinical imagers generally employ a prescan to center the bulk water signal of the object/subject, optimize the flip angle and shim the field. Note that no such “prescan” should be made between direct saturation and CEST scans to maintain the same field reference conditions. For both scans, saturation was accomplished using a rectangular RF pulse before the turbo spin echo (TSE) image acquisition, as previously described by Jones et al. (21 (link)).
The power level needed for each saturation experiment depended on the load and was optimized by measuring sets of Z-spectra under these different conditions. For WASSR, the power and pulse lengths were chosen as small as possible to have sufficient direct saturation, while minimizing any MT effects. For CEST, the maximum pulse length allowed for the body coil within the protected clinical software (500 ms) was used and the power was optimized for maximum effect at the phantom and muscle loads. WASSR was obtained at higher frequency resolution than CEST, but over a smaller frequency range as only the direct saturation region needs to be covered. The WASSR range was chosen sufficiently large to validate the simulated results, consequently leading to a larger number of frequencies needed in vivo than for the phantom.
Single-slice glycogen phantom imaging was performed using SENSE factor = 2, TSE factor [number of refocusing pulses] = 34 (two-shots TSE), TR = 3000 ms, TE = 11 ms, matrix = 128 × 122, FOV = 100 × 100 mm2, slice thickness = 5 mm, NSA = 1. Imaging parameters for human calf muscle experiments were identical to those in phantom experiments except for the following: FOV = 160 × 160 mm2. The saturation spectral parameters for WASSR and CEST are indicated in Table 1.
Publication 2009
Dietary Fiber ECHO protocol Glycogen Homo sapiens Human Body Knee Joint Leg Muscle Tissue Pulse Rate Pulses Radionuclide Imaging SHIMS

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Acceleration Adult Biceps Femoris Cadaver Cerebral Palsy Child Epistropheus Femur Foot Generic Drugs Gomphosis Gravitation Gravity Head Hip Joint Joints Joints, Ankle Knee Joint Muscle, Gastrocnemius Muscle Tissue Pelvis Plant Roots Quadriceps Femoris Rectus Femoris Semimembranosus Tibia Torso Vastus Intermedius Vastus Lateralis Vastus Medialis Vertebrae, Lumbar
After standard quality control procedures, the first step of existing single-cell RNA-seq processing pipelines [1 (link)–3 (link)] is to extract cell barcode and UMI sequences and to add this information to the header of the sequenced read or save it in temporary files. This approach, while versatile, can create many intermediate files on disk for further processing, which can be time- and space-consuming.
Alevin begins with sample-demultiplexed FASTQ files. It quickly iterates over the file containing the barcode reads and tallies the frequency of all observed barcodes (regardless of putative errors). We denote the collection of all observed barcodes as . Whitelisting involves determining which of these barcodes may have derived from a valid cell. When the data has been previously processed by another pipeline, a whitelist may already be available for alevin to use. When a whitelist is not available, alevin uses a two-step procedure for calculating one. An initial draft whitelist is produced using the procedure explained below, to select CBs for initial quantification. This list is refined after per-cell-level quantification estimates are available (see “Final whitelisting (optional)” section) to produce a final whitelist.
To generate a putative whitelist, we follow the approach taken by other dscRNA-seq pipelines by analyzing the cumulative distribution of barcode frequencies and finding the knee in this curve [1 (link), 2 (link)]. Those barcodes occurring after the knee constitute the whitelist, denoted W . We use a Gaussian kernel to estimate the probability density function for the barcode frequency and select the local minimum corresponding to the “knee.” In the case of a user-provided whitelist, the provided W is used as the fixed final whitelist.
Next, we consider those barcodes in E=W to determine, for each non-whitelisted barcode, whether (a) its corresponding reads should be assigned to some barcode in W or (b) this barcode represents some other type of noise or error (e.g., ambient RNA, lysed cell) and its associated reads should be discarded. The approach of alevin is to determine, for each barcode hjE , the set of whitelisted barcodes with which hj could be associated. We call these the putative labels of hj—denoted as (hj). Following the criteria used by previous pipelines [1 (link)], we consider a whitelisted barcode wi to be a putative label for some erroneous barcode hj if hj can be obtained from wi by a substitution, by a single insertion (and clipping of the terminal base) or by a single deletion (and the addition of a valid nucleotide to the end of hj). Rather than applying traditional algorithms for computing the all-versus-all edit-distances directly, and then filtering for such occurrences, we exploit the fact that barcodes are relatively short. Therefore, we can explicitly iterate over all of the valid wiW and enumerate all erroneous barcodes for which this might be a putative label. Let Q(wi,H) be the set of barcodes from E that adhere to the conditions defined above; then, for each hjQ(wi,H), we append wi as putative label for the erroneous barcode hj.
Once all whitelisted barcodes have been processed, each element in E will have zero or more putative labels. If an erroneous barcode has more than one putative label, we prioritize substitutions over insertions and deletions. If this does not yield a single label, ties are broken randomly. If no candidate is discovered for an erroneous barcode, then this barcode is considered “noise,” and its associated reads are simply discarded. Note that, although adopted from existing methods, the alevin initial whitelisting process is designed to output a larger number of CBs.
Publication 2019
Cells Deletion Mutation Gene Deletion Germ Cells Insertion Mutation Knee Joint Nucleotides One-Step dentin bonding system
Currently there is no consensus on the most appropriate testing positions for HHD use, with a recent systematic review demonstrating a variety of methodologies used for lower limb assessment in previous research [25 (link)]. Based on prior research and our own pilot work of assessments in a variety of different positions, we implemented those shown in Fig 1. These testing positions have shown strong reliability for the measurement of isometric strength in previous studies for the hip [36 (link)], knee [37 (link)], and ankle [37 (link)] muscle groups.
Assessment of isometric muscle strength and power was performed with the participants in three positions (seated, supine, and prone); hip flexors, knee extensors, and knee flexors were assessed in a seated position; ankle plantarflexors, ankle dorsiflexors, hip abductors, and hip adductors in a supine position; hip extensors in a prone position. These positions were chosen to minimise changes in position by the participant to enhance the feasibility of testing in a clinical setting. All tests involved maximal voluntary isometric contractions. Assessment using the HHDs was conducted first. The order was randomised for assessor and HHD, however the order of the muscle groups tested was kept consistent as shown in Fig 1; for example if HHD1 was randomly assigned first, all seated muscle groups would be assessed, followed by HHD2 assessing seated muscle groups, with the same order of HHDs for supine and then prone muscle groups. Following a rest period of five minutes, the same protocol was repeated by the second assessor. During pilot testing, problems arose in the assessment of very strong muscle groups, namely the knee extensors and ankle plantarflexors. To assist the assessor in overcoming the force produced by the participant, the plinth was placed close to a wall, which aided the assessors in their resistance of the participants’ contractions for these two muscle groups (see Fig 1B and 1D).
Following HHD testing, the isometric strength and power of participants was then assessed using the KinCom dynamometer utilising the positions described for the HHDs. In order to minimise position changes and reduce time requirements, the order of muscles tested was different during the assessment with the KinCom dynamometer. The order for the KinCom was as follows: knee extensors, knee flexors, hip flexors, hip abductors, hip adductors, hip extensors, ankle plantarflexors, and ankle dorsifexors. Instructions provided to participants for all trials were ‘at the count of three, push/pull as hard and as fast as you can and hold that contraction until I say relax’. Each test lasted between three to five seconds and ended after a steady maximal force was produced by the participant. Participants were instructed to hold the side of the plinth for stabilization (see Fig 1). Constant verbal encouragement was provided throughout the testing. Only the right limb of each participant was assessed to reduce fatigue and the time demands of the testing session. A submaximal practice trial was given for each muscle group on both HHDs and the fixed dynamometer to ensure the participant understood the contraction required. Two trials were recorded for each muscle group, again to minimise the time requirements of testing.
Publication 2015
Ankle Fatigue Isometric Contraction Knee Joint Lower Extremity Muscle Strength Muscle Tissue Neoplasm Metastasis Pemphigus, Benign Familial Sitting
There is no gold standard available in the Netherlands to determine the completeness of the LROI database. We therefore used 2 alternative methods. The data from the LROI were validated against reimbursement data from the national insurance database on healthcare (Vektis ). We also compared the data from the LROI with surgical date data from the HIS of each hospital. Completeness of registration in the LROI was calculated by comparing the number of registrations in the LROI with the number of arthroplasty surgeries based on national health insurance data (Vektis ), and with data from the HIS of each hospital in the Netherlands (for definitions, see box, for surgical codes see Table 2). Completeness based on Vektis data was calculated for the period 2009–2012, while completeness based on HIS data was calculated for 2012 and 2013.
A primary hip arthroplasty was defined as the first time a total, hemi-, or resurfacing prosthesis is placed, to replace a hip joint or part of a hip joint. A primary knee arthroplasty was defined as the first time a unicondylar, patellofemoral, or total prosthesis is placed, to replace a knee joint or part of a knee joint. Revision arthroplasty was defined as any change (replacement, removal, or addition) of 1 or several components of the joint prosthesis. As an aid to selecting the correct surgical procedures from the HIS, specific codes from the diagnosis treatment coding system used in Dutch healthcare were offered at hospitals.
Data from the LROI were retrieved in May 2014 and compared with data from Vektis for hip and knee arthroplasties performed at each hospital. In the analyses, counts were based on the total number of primary and revision arthroplasties (separately for hip and knee joints). Then, for the comparison with data from the HIS in each hospital in the Netherlands, primary and revision arthroplasties were analyzed separately for hip and knee joints. For primary hip arthroplasty, only total hip arthroplasties (THAs) were considered. In cases where the number of registrations per hospital in the LROI exceeded the amount of arthroplasty registrations in the Vektis or HIS data, the number in Vektis/HIS was considered the maximum number. Overall annual results and also hospital-specific results were calculated. Coverage of the LROI (participation of hospitals; see box for definition) was calculated by comparing the number of participating hospitals with the number of hospitals that performed arthroplasty procedures based on Vektis data for each year.
Publication 2015
Arthroplasty Arthroplasty, Replacement Diagnosis Gold Hip Joint Knee Joint Knee Replacement Arthroplasty National Health Insurance Operative Surgical Procedures Prosthesis Total Hip Arthroplasty

Most recents protocols related to «Knee Joint»

Example 6

4 mm2 cartilage explants were taken from non-lesion areas of OA patient's knee articular cartilage (n=5) and randomly assigned to different experimental treatment conditions (4 explants per treatment group). After a 24 h equilibration period the explants were treated with BMP-7 (1 nM) or the 12-mer peptide according to SEQ ID NO: 16 (10 nM) for 24 h. Hypertrophic gene expression was determined via qRT-PCR and normalized for 28S rRNA levels. After treatment with BMP-7 or the 12 mer we observed a downregulation of pro-hypertrophic genes, such as Col10a1 (FIG. 10A) and MMP13 (FIG. 10B). These results are in line with the effects described above and show the BMP-7 mimicking bioactivity of the peptides according to the invention.

Patent 2024
Aftercare Bone Morphogenetic Protein 7 Cartilage Cartilages, Articular Down-Regulation Gene Expression Genes, vif Hypertrophy Knee Joint MMP13 protein, human Peptides RNA, Ribosomal, 28S Therapies, Investigational
Not available on PMC !

Example 4

Amino acid sequences of region-A are 100% homologous between human and mouse. In order to further establish the in vivo activity of the peptides for use according to the invention, representative peptides may be tested in a well-accepted model for post-traumatic OA, the DMM model. The medial meniscus may be destabilized in 12 weeks old C57BL/6 mice. One week after DMM induction, peptides may be administered intra-articularly by twice-weekly injections as described previously. Dose may be based on intra-articular BMP-7 studies in which weekly injections of 250 ng BMP-7 in a rat knee joint (in 100 μl) showed favorable outcomes. As 10 μl can be injected in an OA mouse joint an equivalent amount of 25 ng peptide in this volume may be injected per knee joint. An amount of 2.5 and 0.25 ng peptide may also be tested in 2 additional groups to determine the pharmacological potency of the peptide. Saline injections may be used as controls. The sample size of this experiment is advantageously 8 mice per group. Animals may be sacrificed at consecutive time points after start of peptide treatment (2, 4, 8 weeks). Knee joints may be processed for (immuno)histochemical analyses and OARSI scoring (Safranin-O; modified Pritzker).

Patent 2024
Aftercare Amino Acid Sequence Animals Bone Morphogenetic Protein 7 Homo sapiens Joint Loose Bodies Joints Knee Joint Meniscus, Medial Mice, House Mice, Inbred C57BL Peptides safranine T Saline Solution

Example 6

A plain radiography of patient X's knee is undertaken to evaluate the path of least obstruction and maximal access to the synovial cavity. This access can be superolateral, supermedial or anteromedial/anterolateral. The knee injection site is selected based on the bony anatomy of the patient X's knee joint. In the case of patient X, a superolateral knee injection site is chosen.

Patient X lies supine with the knee fully extended with a thin pad support to facilitate relaxation. The injection site is marked with a pen to leave an impression on the skin and the skin is cleaned with alcohol swabs.

A clinician's thumb is used to gently stabilize the patella while a 25 G 1.5″ needle containing the degradable drug delivery composition with celecobix is inserted underneath the supralateral surface of the patella aimed toward the center of the patella and then directed slightly posteriorly and inferomedially into the knee joint. The content of the needle is then injected and the needle is withdrawn from the knee.

Patent 2024
Bones Dental Caries Drug Delivery Systems Ethanol Intra-Articular Injections Joints Knee, Fractured Knee Joint Needles Patella Patients Skin Thumb X-Rays, Diagnostic
Not available on PMC !

Example 1

Provided herein is an exemplary embodiment of workflow for tracking and registering a knee joint using markers that are drilled into the in tibia and femur of the knee joint in the patient and protrude out from their placement site. The placement of the marker in order to track and register the bones of the knee joint is an invasive procedure that damages the tissue at and around the knee joint. The marker is used in marker-based tracking to track and register the knee joint and in robot-assisted surgical systems. Such invasive fixation of markers to bones may lead to complications, infections, nerve injury, and bone fracture. The marker fixation may reduce the flexibility during the procedure as the protruding markers may get in the way during the procedure. The surgical procedure may take longer to fix the marker into place than a markerless approach.

Patent 2024
Bones Femur Fracture, Bone Infection Injuries Knee Joint Nervousness Operative Surgical Procedures Patients Robotic Surgical Procedures Tibia Tissues
In this study, mRNA was isolated from cultured cells and knee articular cartilage tissues. The cultured cells were rinsed with PBS and lysed in RNA-Solv® Reagent (Omega Bio-tek, Norcross, GA, USA). The knee cartilage samples were placed in paired RNase-Free 1.5 EP tubes with four ground beads (5 mm in diameter) and frozen with liquid nitrogen. Subsequently, the tissues were pulverized and homogenized using Tissuelyser-24 (Jingxin, Shanghai, China). The TissueLyser was operated twice for 30 s at 45 Hz. The above tissue powder (50–100 mg) was lysed in Omega RNA-Solv® Reagent and RNA was isolated using the E.Z.N.A.® Total RNA Kit I (Omega Bio-tek) according to manufacturer’s protocol. MiRNA levels were extracted using a miRNA Isolation Kit (Ambion). RNA was stored at − 80 °C. Reverse transcription was performed using 1.0 µg total RNA and then used to prepare cDNA using miRNA and HiFiScript cDNA kits (CWBIO, Beijing, China), which were used to investigate the expression of miRNA and mRNA, respectively. All qPCRs were performed in a 20 µL volume using appropriate primers (1 µL; Sangon Biotech, Shanghai, China), cDNA (1 µL), and a ROX-containing UltraSYBR Mixture (CWBIO) with an ABI 7500 Sequencing Detection instrument (Applied Biosystems, CA, USA). The thermocycler settings were as follows: 40 cycles of 95 °C for 5 s and 60 °C for 24 s. U6 was used as an internal control for microRNA, whereas β-actin served as the control for messenger RNA. The cycle threshold (Ct) values were collected and normalized to the level of U6 or β-actin, with three samples per group. The relative mRNA level of each target gene was calculated by using the 2−ΔΔCt method. Primer sequences are shown in Table 1.

Primer sequences for qPCR

GenePrimers
MiR-760

Forward: UUCUCCGAACGUGUCACGUTT

Reverse: ACGUGACACGUUCGGAGAATT

MMP3

Forward: AGTCTTCCAATCCTACTGTTGCT

Reverse: TCCCCGTCACCTCCAATCC

MMP13

Forward: ACTGAGAGGCTCCGAGAAATG

Reverse: GAACCCCGCATCTTGGCTT

ADAMTS4

Forward: GAGGAGGAGATCGTGTTTCCA

Reverse: CCAGCTCTAGTAGCAGCGTC

COL2A1

Forward: TGGACGATCAGGCGAAACC

Reverse: GCTGCGGATGCTCTCAATCT

Aggrecan

Forward: ACTCTGGGTTTTCGTGACTCT

Reverse: ACACTCAGCGAGTTGTCATGG

HBEGF

Forward: ATCGTGGGGCTTCTCATGTTT

Reverse: TTAGTCATGCCCAACTTCACTTT

CBL

Forward: TGGTGCGGTTGTGTCAGAAC

Reverse: GGTAGGTATCTGGTAGCAGGTC

CAMK2G

Forward: ACCCGTTTCACCGACGACTA

Reverse: CTCCTGCGTGGAGGTTTTCTT

MAP2K1

Forward: CAATGGCGGTGTGGTGTTC

Reverse: GATTGCGGGTTTGATCTCCAG

ADCY1

Forward: AGGCACGACAATGTGAGCATC

Reverse: TTCATCGAACTTGCCGAAGAG

RPS6KA3

Forward: CGCTGAGAATGGACAGCAAAT

Reverse: TCCAAATGATCCCTGCCCTAAT

U6

Forward: CTCGCTTCGGCAGCACA

Reverse: AACGCTTCACGAATTTGCGT

β-actin

Forward: AGATGTGGATCAGCAAGCAG

Reverse: GCGCAAGTTAGGTTTTGTCA

Publication 2023
Actins angiogenin Cartilage Cartilages, Articular Cultured Cells DNA, Complementary Freezing Genes isolation Knee Joint MicroRNAs Nitrogen Oligonucleotide Primers Powder Reverse Transcription RNA, Messenger RNA I Tissues

Top products related to «Knee Joint»

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, Sweden, Canada, United Kingdom
Visual3D is a software application developed by C-Motion for analyzing and visualizing motion capture data. It provides a comprehensive set of tools for processing and interpreting three-dimensional movement data obtained from various motion capture systems.
Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Denmark, Israel, Macao, Ireland, Netherlands, Austria, Hungary, Holy See (Vatican City State), Sweden, Brazil, Argentina, India, Poland, Morocco, Czechia
DMEM/F12 is a cell culture medium developed by Thermo Fisher Scientific. It is a balanced salt solution that provides nutrients and growth factors essential for the cultivation of a variety of cell types, including adherent and suspension cells. The medium is formulated to support the proliferation and maintenance of cells in vitro.
Sourced in United States, United Kingdom, Japan
The Biodex System 3 is a versatile and precise rehabilitation and testing system. It is designed to evaluate and treat a wide range of musculoskeletal disorders and neurological conditions. The system provides objective data and metrics to support clinical decision-making.
Sourced in United States, Germany, Sweden, Macao
The MBSA is a compact and versatile laboratory equipment designed for molecular biology applications. It provides precise and consistent temperature control for various sample types, enabling reliable performance of essential laboratory techniques.
Sourced in United States, Germany, China, Sao Tome and Principe, Macao, Japan, United Kingdom, Italy, Switzerland, Canada, France
Collagenase type II is a purified enzyme derived from Clostridium histolyticum. It is used for the dissociation of a variety of cell types, particularly those with a high collagen content, such as cartilage and connective tissue.

More about "Knee Joint"

The knee joint is a complex hinge articulation that connects the thigh and lower leg, enabling flexion, extension, and limited rotation.
It comprises the femur, tibia, and patella bones, as well as ligaments, tendons, and cartilage that facilitate smooth movement and weight-bearing.
Proper knee joint function is essential for ambulation and many physical activities.
Conditions affecting the knee joint, such as osteoarthritis, ligament tears, and patellofemoral pain, can lead to pain, stiffness, and impaired mobility.
Accurate assessment and treatment of knee joint disorders is a crucial area of medical research and clinical practice.
Researchers may utilize various tools and techniques to study the knee joint, including FBS (Fetal Bovine Serum) and DMEM (Dulbecco's Modified Eagle Medium) for cell culture, MATLAB for data analysis, and Visual3D for motion capture.
The Biodex System 3 is a popular isokinetic dynamometer used to evaluate knee joint function.
Cartilage and ligament injuries may be studied using techniques like MBSA (Microbubble-Assisted Sonoporation) and Collagenase type II digestion.
Antibiotic agents like Streptomycin and Penicillin are often used to maintain a sterile environment during in vitro experiments.
By leveraging the power of AI-driven protocol analysis, researchers can optimize their knee joint studies, enhance reproducibility, and identify the most effective products and methodologies.